comprehensive -WSS

comprehensive

author：focus 2025-10-01 21:36:41 - browse：32

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.

The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%.

Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm. The medicine was the first of a new class of disease-modifying Alzheimer’s drugs to be approved by the Food and Drug Administration. But doubts about the quality of the data behind the medicine meant that Medicare wouldn’t pay for it and doctors did not prescribe it. The resulting financial disaster cleaned out Biogen’s executive suite.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Caribou posts encouraging results on off

Wikipedia

WSS

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

New report analyzes digital physical therapy solutions' effectiveness

Study: Why relieving medical debt did not improve financial outcomes

Health care court cases: Humana, Sutter, Novant

entertainment

comprehensive

leisure time

Medical records are filled with copy

Scientists grapple with ethics of stem cell research

BioMarin wins approval for gene therapy to treat hemophilia A

New report analyzes digital physical therapy solutions' effectiveness

United colonoscopy coverage change 'may cost lives,' doctors say

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Supreme Court strikes down use of affirmative action

After a decade, new Gardasil ad campaign gets it (mostly) right

What does generative AI mean for health care? We asked experts

The system is set up to fail children with medical complexity

focus

Teladoc has a new CEO, but challenges remain the same

'CMA Fest' 2023: How to watch, who is performing and more

Health care court cases: Humana, Sutter, Novant

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Lilly's Alzheimer's drug donanemab backed by FDA advisers

The system is set up to fail children with medical complexity

hotspot

explore

Wikipedia

focus